TABLE 2.
Cross-resistance profiles of RSV604- and A-33903-resistant mutants
| Compound | RSV604 resistance
|
A-33903 resistance
|
||||
|---|---|---|---|---|---|---|
| EC50 (μM)a
|
Fold increase in resistanceb | EC50 (μM)a
|
Fold increase in resistanceb | |||
| DMSO-passaged WT | Resistant mutant | DMSO-passaged WT | Resistant mutant | |||
| RSV604 | 0.6 | 30.4 | 50.7 | 0.7 | 2.7 | 3.9 |
| A-33903 | 8.1 | >100 | >12.3 | 8.9 | 27.6 | 3.1 |
| A-60445 | ND | ND | ND | 0.4 | 1.3 | 3.3 |
| A-64315 | 0.4 | 16.9 | 42.3 | ND | ND | ND |
| A-57156c | <0.16 | <0.16 | ∼1 | <0.16 | <0.16 | ∼1 |
| Ribavirin | 20.7 | 17.6 | 0.85 | ND | ND | ND |
a
Determined by plaque reduction assay. A plaque-picked RSV604 mutant from passage 2 and a plaque-picked A-33903 mutant from passage 2 were tested for sensitivity to the indicated compounds. ND, not determined.
b
Increase in resistance of the mutant compared to its WT virus control.
c
Fusion inhibitor.